Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

NCT02052128 is registered in ClinicalTrials.gov with Arno Therapeutics as lead sponsor.

NCT NCT02052128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02052128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Lead sponsor
Arno Therapeutics
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2014
Completion date
April 30, 2016
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

progesterone receptor positive tumor: max 1 line of prior chemotherapy, no prior hormone therapy